Abstract

 CADTH recommends that Rinvoq be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have demonstrated prior treatment failure (i.e., an inadequate response to, loss of response to, or intolerance to at least 1 of conventional therapy and/or biologic therapy), if certain conditions are met.
 Rinvoq should be covered for a similar patient population and in a similar way to other drugs currently reimbursed by public drug plans for the treatment of moderately to severely active UC.
 Rinvoq should only be reimbursed if it is prescribed by a physician experienced in treating UC, the dosage does not exceed the product monograph’s recommended dosage, and it is not used in combination with biologics for UC. It should not cost more than other biologics or targeted synthetic drugs covered by the public drug plans for the treatment of moderately to severely active UC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
